Anna Panovská

Low-burden <i>TP53</i> mutations in CLL: clinical impact and clonal evolution within the context of different treatment options

Jitka Malčíková, Šárka Pavlová, Barbara Vonková et al. · Blood · 2021 · 50 citations · Full text

Hematological Malignancy, Tp53 Status, Oncology +15

FoxO1-GAB1 axis regulates homing capacity and tonic AKT activity in chronic lymphocytic leukemia

Václav Šeda, Eva Vojáčková, Laura Ondrišová et al. · Blood · 2021 · 33 citations · Full text

Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categories

Michael Fiegl, Martin Erdel, Ingeborg Tinhofer et al. · Annals of Oncology · 2010 · 27 citations · Full text

Retrospective Study, Hematological Malignancy, Lymphoid Neoplasia +12

Rituximab in combination with high-dose dexamethasone for the treatment of relapsed/refractory chronic lymphocytic leukemia

Lukáš Smolej, Michael Doubek, Anna Panovská et al. · Leukemia Research · 2012 · 26 citations

Hematological Malignancy, Lymphoid Neoplasia, Oncology +7

Chronic Lymphocytic Leukemia and Focusing on Epidemiology and Management in Everyday Hematologic Practice: Recent Data From the Czech Leukemia Study Group for Life (CELL)

Anna Panovská, Michael Doubek, Yvona Brychtová · Clinical Lymphoma Myeloma & Leukemia · 2010 · 25 citations

Hematological Malignancy, Lymphoid Neoplasia, Oncology +7